Details of the Drug
General Information of Drug (ID: DMIAQX4)
Drug Name |
Heptulose-2-Phosphate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Heptulose-2-Phosphate; 6gpb; H2P; Heptulose-2-P; 1-Deoxygluco-heptulose 2-phosphate; Heptulose 2-phosphate; AC1Q6S5N; AC1L3Z5G; SCHEMBL4312544; 1-deoxy-2-o-phosphono-; A-d-gluco-hept-2-ulopyranose; 1-Deoxy-D-gluco-heptulose 2-phosphate; DB04195; 92642-58-5; 1-deoxy-2-O-phosphono-alpha-D-gluco-hept-2-ulopyranose; alpha-D-gluco-2-Heptulopyranose, 1-deoxy-, 2-(dihydrogen phosphate); [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-methyloxan-2-yl] dihydrogen phosphate
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 274.16 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -3.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 6 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 9 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||